However, the HBV and HCV treatment groups did not reach statistical significance, which is likely due to the treatment of HBV and HCV reducing the progression of liver cancer and potentially masking the LFC-induced protective effect.
← all excerpts
LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study.
1
—
—